Abstract
The chloro-bridged heterobimetallic complex (eta(6)-hexamethylbenzene)Ru(dmp)(mu-Cl)(2)Sn(CH3)(2)Cl-2 was designed, synthesized, and characterized by various spectroscopic methods, viz. IR, H-1 and C-13 NMR, and ESI MS, and single-crystal X-ray crystallography as an approach toward multitargeting metal-based potential anticancer drug candidates. In vitro DNA binding studies confirmed the binding affinity of the complex toward the minor groove of DNA, which is further validated by docking studies. Furthermore, the complex exhibited significant inhibitory effects on topoisomerase I alpha at a very low concentration (similar to 8 mu M). The cytotoxicity of the complex against He La and HepG2 cancer cell lines was evaluated, which revealed significant regression in cancerous cells in comparison with the standard drug.